Skip to main content

Table 3 In-dwell characteristics and adverse events of PORT-inserted patients, stratified by solid tumours versus the control group

From: Impact of the COVID-19 pandemic on subcutaneous venous port-related complications in patients with cancer: a retrospective case–control study

Complications, haematological cancer — solid tumours 2020 solid tumours Control group HR 95% CI p-value
n = 201 n = 168
Total catheter days 29,071 37,469
CD per patient, median (IQR) 175 (69) 217 (179) < 0.001
Mortality, n (%) 36 (17.9) 34 (20.2) 1.5 0.9–2.6 0.121
DVT, n (%) 2 (1.0) 1 (0.6) 2.0 0.2–21.9 0.578
DVT/1000 CD 0.07 0.03
Days to DVT, median (IQR) 85 (−)
All catheter infections, n (%) 9 (4.5) 16 (9.5) 0.6 0.3–1.4 0.211
Infection/1000 CD 0.31 0.43
Local infection, n (%) 9 (4.5) 15 (8.9)
CRI, n (%) 3 (1.5)
CRBSI, n (%) 2 (1.0) 2 (1.2) 1.8 0.2–20.1 0.623
CRBSI/1000 CD 0.07 0.05
Days to infection median (IQR) 56 (85) 46 (96) 0.428
Haematoma, n (%) 10 (5.0) 2 (1.2) 0.043
Antibiotics, n (%) 22 (10.1) 2 (1.2)    < 0.001
Mechanical, n (%) 6 (3.0) 7 (4.2) 1.0 0.3–3.0 0.945
Mechanical/1000 CD 0.21 0.19
Days to mechanical event median (IQR) 16 (57) 122 (107) 0.015
Occlusion, n (%) 18 (9.0) 1 (0.6) 16.2 2.2–121.1 0.007
Occlusion/1000 CD 0.62 0.03   
Days to occlusion median (IQR) 17 (43) – (−)
All grade adverse events, n (%) 37 (18.4) 25 (14.9) 1.7 1.0–2.9 0.068
All grade adverse events/1000 CD 1.27 0.67
Days to all grade adverse events median (IQR) 22 (63) 60 (114) 0.001
  1. HR hazard ratio, CI confidence interval, CD catheter days, IQR interquartile range, DVT deep venous thrombosis, CRI catheter-related infection, CRBSI catheter-related bloodstream infection